Resistance and Progression Mechanisms in Prostate Cancer
CLINICAL RESEARCHERS
- Maria Pané Foix
POSTDOCTORAL RESEARCHERS (R2)
- Katia Ruggero
- Rana El Bizri
PREDOCTORAL RESEARCHERS (R1)
- Sonia Farran Matas
- Adrian Martinez Tébar
SCIENTIFIC SUPPORT
- Xieng Chen Wang
- Luis Palomero Lopez De Armentia
Cancer
Oncobell
Scientific production
4
PAPERS
2 PUBLICATIONS IN FIRST QUARTILE
Selected publications
- Costas L., Palomero L., Benavente Y., Guardiola M., Frias-Gomez J., Pavón M.Á., Climent M., Martinez J.M., Barahona M., Salinas M., Pineda M., Bianchi I., Reventós J., Capellà G., Diaz M., Vidal A., Piulats J.M., Ponce J., Brunet J., Bosch F.X., Matias-Guiu X., Alemany L., de Sanjosé S., Aytés Á.. Defining a mutational signature for endometrial cancer screening and early detection. CANCER EPIDEMIOLOGY. 10.1016/j.canep.2019.06.003
- Costas L., Frias-Gomez J., Guardiola M., Benavente Y., Pineda M., Pavón M.Á., Martínez J.M., Climent M., Barahona M., Canet J., Paytubi S., Salinas M., Palomero L., Bianchi I., Reventós J., Capellà G., Diaz M., Vidal A., Piulats J.M., Aytés Á., Ponce J., Brunet J., Bosch F.X., Matias-Guiu X., Alemany L., de Sanjosé S., on behalf of the Screenwide Team. New perspectives on screening and early detection of endometrial cancer. INTERNATIONAL JOURNAL OF CANCER. 10.1002/ijc.32514
- Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E . BRCA2 and Other DDR Genes in Prostate Cancer.. CANCERS. 10.3390/cancers11030352
Research highlights
PROJECTS
6 Ongoing projects
Selected projects
- Therapeutic landscape and predictive biomarkers for DNA damage repair pathway inhibitors in advanced prostate cancer (1/1/2020 – 31/12/2022) PI: AYTES MENESES, ALVARO. Funder: FIS-Instituto de Salud Carlos III.
- Mechanisms ant therapeutic targeting of NSD2 in advanced prostate cancer (30/9/2018 – 29/9/2021) PI: AYTES MENESES, ALVARO. Funder: DEPARTMENT OF THE US ARMY.
- Investigating causal mechanisms and novel therapeutic targets in CRPC after AR blockade failure. (29/1/2016 – 28/1/2019) PI: AYTES MENESES, ALVARO. Funder: EAU RESEARCH FOUNDATION.
- Mecanismos epigenéticos de resistencia a la castración en cancer de próstata: oportunidades terapéuticas en combinación con antagonistas del receptor de andrógenos. (1/1/2017 – 31/12/2019) PI: AYTES MENESES, ALVARO. Funder: FIS-Instituto de Salud Carlos III.
- Proyectos Integrados de Excelencia-ISCIII-PIE. (1/1/2017 – 31/12/2019) PI: AYTES MENESES, ALVARO. Funder: FIS-Instituto de Salud Carlos III.